Overall, the data indicates Celastrol can significantly inhibit VCaP cell growth in vivo by targeting AR-ERG-NF-κB signal and suggests Celastrol may have therapeutic potential for T/E fusion carrying PCa. This evidence concerns the gene ERG and posterior cortical atrophy.